These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 21373319)

  • 1. Etoricoxib-induced life-threatening hyperkalemia and acute kidney dysfunction against the background of telmisartan and a low sodium diet.
    Tripathy S; Dash SC
    Int J Emerg Med; 2010 Aug; 3(4):443-6. PubMed ID: 21373319
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tolerability of selective cyclooxygenase 2 inhibitors used for the treatment of rheumatological manifestations of inflammatory bowel disease.
    Miao XP; Li JS; Ouyang Q; Hu RW; Zhang Y; Li HY
    Cochrane Database Syst Rev; 2014 Oct; 2014(10):CD007744. PubMed ID: 25340915
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Renal effects of etoricoxib and comparator nonsteroidal anti-inflammatory drugs in controlled clinical trials.
    Curtis SP; Ng J; Yu Q; Shingo S; Bergman G; McCormick CL; Reicin AS
    Clin Ther; 2004 Jan; 26(1):70-83. PubMed ID: 14996519
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Severe bradycardia from severe hyperkalemia: Patient characteristics, outcomes and factors associated with hemodynamic support.
    Drumheller BC; Tuffy E; Gibney F; Stallard S; Siewers C; Korvek S
    Am J Emerg Med; 2022 May; 55():117-125. PubMed ID: 35306438
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tetraparesis and failure of pacemaker capture induced by severe hyperkalemia: case report and systematic review of available literature.
    Sanson G; Russo S; Iudicello A; Schiraldi F
    J Emerg Med; 2015 May; 48(5):555-61.e3. PubMed ID: 25766426
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acute Ascending Flaccid Paralysis Secondary to Multiple Trigger Factor Induced Hyperkalemia.
    Hemachandra KHDT; Chandimal Dayasiri MBK; Kannangara T
    Case Rep Neurol Med; 2018; 2018():6360381. PubMed ID: 30002937
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Electrolyte abnormalities and metabolic acidosis in two Duchenne muscular dystrophy patients with advanced congestive heart failure].
    Matsumura T; Saito T; Miyai I; Nozaki S; Kang J
    Rinsho Shinkeigaku; 2000 May; 40(5):439-45. PubMed ID: 11002725
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of Patiromer on Serum Potassium Level in Patients With Hyperkalemia and Diabetic Kidney Disease: The AMETHYST-DN Randomized Clinical Trial.
    Bakris GL; Pitt B; Weir MR; Freeman MW; Mayo MR; Garza D; Stasiv Y; Zawadzki R; Berman L; Bushinsky DA;
    JAMA; 2015 Jul; 314(2):151-61. PubMed ID: 26172895
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gastrointestinal and cardiovascular risk of non-selective NSAIDs and COX-2 inhibitors in elderly patients with knee osteoarthritis.
    Turajane T; Wongbunnak R; Patcharatrakul T; Ratansumawong K; Poigampetch Y; Songpatanasilp T
    J Med Assoc Thai; 2009 Dec; 92 Suppl 6():S19-26. PubMed ID: 20128070
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of angiotensin-converting enzyme inhibitors in patients with heart failure and renal insufficiency: how concerned should we be by the rise in serum creatinine?
    Ahmed A
    J Am Geriatr Soc; 2002 Jul; 50(7):1297-300. PubMed ID: 12133029
    [TBL] [Abstract][Full Text] [Related]  

  • 11.
    Mehandru SK; Haroon A; Masud A; Shah J; Kaur S; Masud A; Hossain A; Asif A; Vachharajani TJ
    Saudi J Kidney Dis Transpl; 2020; 31(5):1134-1139. PubMed ID: 33229781
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of ramipril and telmisartan on serum potassium and its association with cardiovascular and renal events: results from the ONTARGET trial.
    Heerspink HJ; Gao P; de Zeeuw D; Clase C; Dagenais GR; Sleight P; Lonn E; Teo KT; Yusuf S; Mann JF
    Eur J Prev Cardiol; 2014 Mar; 21(3):299-309. PubMed ID: 24191305
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Emergency Department Presentation of Life-threatening Symptomatic Hyperkalemia From an Angiotensin Receptor Blocker in a Low-risk Individual.
    Dockery S; Dupré A; Deflorio P; Murray BP
    Mil Med; 2023 Aug; 188(9-10):3242-3247. PubMed ID: 36454619
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs (etodolac, meloxicam, celecoxib, rofecoxib, etoricoxib, valdecoxib and lumiracoxib) for osteoarthritis and rheumatoid arthritis: a systematic review and economic evaluation.
    Chen YF; Jobanputra P; Barton P; Bryan S; Fry-Smith A; Harris G; Taylor RS
    Health Technol Assess; 2008 Apr; 12(11):1-278, iii. PubMed ID: 18405470
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hyperkalemia-induced paralysis.
    Wilson NS; Hudson JQ; Cox Z; King T; Finch CK
    Pharmacotherapy; 2009 Oct; 29(10):1270-2. PubMed ID: 19792996
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hyperkalemia in outpatients using angiotensin-converting enzyme inhibitors. How much should we worry?
    Reardon LC; Macpherson DS
    Arch Intern Med; 1998 Jan; 158(1):26-32. PubMed ID: 9437375
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hyporeninemic hypoaldosteronism in a patient with diabetes mellitus: an unforgettable case report.
    Chelaghma N; Oyibo SO
    Int Med Case Rep J; 2018; 11():69-72. PubMed ID: 29662328
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cyclo-oxygenase-2 inhibitors: when should they be used in the elderly?
    Savage R
    Drugs Aging; 2005; 22(3):185-200. PubMed ID: 15813652
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hyperkalemia in ambulant postcardiac surgery patients during combined therapy with angiotensin-converting enzyme inhibitor, spironolactone, and diet rich in potassium: A report of two cases and review of literature.
    Dixit A; Majumdar G; Tewari P
    Ann Card Anaesth; 2019; 22(2):162-168. PubMed ID: 30971598
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of rofecoxib, celecoxib, and naproxen on renal function in elderly subjects receiving a normal-salt diet.
    Schwartz JI; Vandormael K; Malice MP; Kalyani RN; Lasseter KC; Holmes GB; Gertz BJ; Gottesdiener KM; Laurenzi M; Redfern KJ; Brune K
    Clin Pharmacol Ther; 2002 Jul; 72(1):50-61. PubMed ID: 12152004
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.